ARTICLE | Clinical News

Biotie, Lundbeck report Nalmefene data

June 16, 2011 12:08 AM UTC

Biotie Therapies Corp. (HSE:BTH1V) and partner H. Lundbeck A/S (CSE:LUN) reported pooled data from three Phase III trials in about 2,000 patients showing that oral nalmefene led to at least a 50% reduction in heavy drinking days from baseline after six months of treatment. Heavy drinking days were defined as at least five drinks per day for men and at least 4 drinks per day for women. Furthermore, data from one of the trials, the 12-month safety Phase III SENSE trial in about 650 patients, showed that the treatment effect was maintained after one year of treatment. The partners also said that some endpoints were not statistically significant at every time point, but would not give details. ...